EFICACITE ANTI-ANGINEUSE DU BEPRIDOL, INHIBITEUR CALCIQUE D'ACTION PROLONGEE: RESULTATS D'UNE ETUDE CONTROLEE CONTRE PLACEBO, MULTICENTRIQUE, DE 10 SEMAINES

Translated title of the contribution: Antianginal efficacy of bepridil, a long acting calcium channel blocker: Results of a 10 week, multicenter, placebo controlled study

Joseph S Alpert, J. M. Gore, R. Dibianco

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Bepridil, a new slow channel blocking agent with a plasma half life of > 50 hours, was compared to placebo in 77 patients with chronic angina, each of whom had ≥ 3 anginal attacks/week and a positive treadmill exercise test characterized by pain and an ST segment change ≥0.1 mV. The effects on resting and maximal exercise hemodynamics, angina frequency and NTG tablet consumption were assessed during 5 sequential 2 week treatment phases (initial placebo, bepridil 200 mg, 30 mg and 400 mg per day followed by a final placebo phase). In addition, QD verses BID regimens were compared in double blind fashion. Bepridil (300 mg/day) reduced the angina frequency 61% (from 8,8 ± 10 (SD) to 3.4 ± 6 attacks/week, p <0.001) and NTG use 70% (p <0.001). Bepridil improved the exercise duration 25% (from 7.2 ± 2.4 to 9.0 ± 2.6 minutes, p <0.001) and the exercise work by 35% (p <0.001) without producing changes in heart rate or blood pressure. The efficacy of QD or BID administrations were similar. Bepridil (200 mg/day) produced less improvement than 300 mg/day; whereas 400 mg/day added few further benefits. No peripheral vascular, AV nodal or adverse inotropic or electrocardiographic effects were observed. A minority of patients reported tremor and/or minor GI disturbances. In this large group of patients with chronic angina, bepridil was found to be an effective and well tolerated antianginal agent when given once daily.

Original languageFrench
Title of host publicationRevue de Medecine
Pages1307-1311
Number of pages5
Volume24
Edition28
StatePublished - 1983
Externally publishedYes

Fingerprint

Bepridil
Calcium Channel Blockers
Placebos
Exercise
Exercise Test
Tremor
Tablets
Blood Vessels
Half-Life
Heart Rate
Hemodynamics
Blood Pressure
Pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

EFICACITE ANTI-ANGINEUSE DU BEPRIDOL, INHIBITEUR CALCIQUE D'ACTION PROLONGEE : RESULTATS D'UNE ETUDE CONTROLEE CONTRE PLACEBO, MULTICENTRIQUE, DE 10 SEMAINES. / Alpert, Joseph S; Gore, J. M.; Dibianco, R.

Revue de Medecine. Vol. 24 28. ed. 1983. p. 1307-1311.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{5c1363799ae546a39c8e8596555fe567,
title = "EFICACITE ANTI-ANGINEUSE DU BEPRIDOL, INHIBITEUR CALCIQUE D'ACTION PROLONGEE: RESULTATS D'UNE ETUDE CONTROLEE CONTRE PLACEBO, MULTICENTRIQUE, DE 10 SEMAINES",
abstract = "Bepridil, a new slow channel blocking agent with a plasma half life of > 50 hours, was compared to placebo in 77 patients with chronic angina, each of whom had ≥ 3 anginal attacks/week and a positive treadmill exercise test characterized by pain and an ST segment change ≥0.1 mV. The effects on resting and maximal exercise hemodynamics, angina frequency and NTG tablet consumption were assessed during 5 sequential 2 week treatment phases (initial placebo, bepridil 200 mg, 30 mg and 400 mg per day followed by a final placebo phase). In addition, QD verses BID regimens were compared in double blind fashion. Bepridil (300 mg/day) reduced the angina frequency 61{\%} (from 8,8 ± 10 (SD) to 3.4 ± 6 attacks/week, p <0.001) and NTG use 70{\%} (p <0.001). Bepridil improved the exercise duration 25{\%} (from 7.2 ± 2.4 to 9.0 ± 2.6 minutes, p <0.001) and the exercise work by 35{\%} (p <0.001) without producing changes in heart rate or blood pressure. The efficacy of QD or BID administrations were similar. Bepridil (200 mg/day) produced less improvement than 300 mg/day; whereas 400 mg/day added few further benefits. No peripheral vascular, AV nodal or adverse inotropic or electrocardiographic effects were observed. A minority of patients reported tremor and/or minor GI disturbances. In this large group of patients with chronic angina, bepridil was found to be an effective and well tolerated antianginal agent when given once daily.",
author = "Alpert, {Joseph S} and Gore, {J. M.} and R. Dibianco",
year = "1983",
language = "French",
volume = "24",
pages = "1307--1311",
booktitle = "Revue de Medecine",
edition = "28",

}

TY - CHAP

T1 - EFICACITE ANTI-ANGINEUSE DU BEPRIDOL, INHIBITEUR CALCIQUE D'ACTION PROLONGEE

T2 - RESULTATS D'UNE ETUDE CONTROLEE CONTRE PLACEBO, MULTICENTRIQUE, DE 10 SEMAINES

AU - Alpert, Joseph S

AU - Gore, J. M.

AU - Dibianco, R.

PY - 1983

Y1 - 1983

N2 - Bepridil, a new slow channel blocking agent with a plasma half life of > 50 hours, was compared to placebo in 77 patients with chronic angina, each of whom had ≥ 3 anginal attacks/week and a positive treadmill exercise test characterized by pain and an ST segment change ≥0.1 mV. The effects on resting and maximal exercise hemodynamics, angina frequency and NTG tablet consumption were assessed during 5 sequential 2 week treatment phases (initial placebo, bepridil 200 mg, 30 mg and 400 mg per day followed by a final placebo phase). In addition, QD verses BID regimens were compared in double blind fashion. Bepridil (300 mg/day) reduced the angina frequency 61% (from 8,8 ± 10 (SD) to 3.4 ± 6 attacks/week, p <0.001) and NTG use 70% (p <0.001). Bepridil improved the exercise duration 25% (from 7.2 ± 2.4 to 9.0 ± 2.6 minutes, p <0.001) and the exercise work by 35% (p <0.001) without producing changes in heart rate or blood pressure. The efficacy of QD or BID administrations were similar. Bepridil (200 mg/day) produced less improvement than 300 mg/day; whereas 400 mg/day added few further benefits. No peripheral vascular, AV nodal or adverse inotropic or electrocardiographic effects were observed. A minority of patients reported tremor and/or minor GI disturbances. In this large group of patients with chronic angina, bepridil was found to be an effective and well tolerated antianginal agent when given once daily.

AB - Bepridil, a new slow channel blocking agent with a plasma half life of > 50 hours, was compared to placebo in 77 patients with chronic angina, each of whom had ≥ 3 anginal attacks/week and a positive treadmill exercise test characterized by pain and an ST segment change ≥0.1 mV. The effects on resting and maximal exercise hemodynamics, angina frequency and NTG tablet consumption were assessed during 5 sequential 2 week treatment phases (initial placebo, bepridil 200 mg, 30 mg and 400 mg per day followed by a final placebo phase). In addition, QD verses BID regimens were compared in double blind fashion. Bepridil (300 mg/day) reduced the angina frequency 61% (from 8,8 ± 10 (SD) to 3.4 ± 6 attacks/week, p <0.001) and NTG use 70% (p <0.001). Bepridil improved the exercise duration 25% (from 7.2 ± 2.4 to 9.0 ± 2.6 minutes, p <0.001) and the exercise work by 35% (p <0.001) without producing changes in heart rate or blood pressure. The efficacy of QD or BID administrations were similar. Bepridil (200 mg/day) produced less improvement than 300 mg/day; whereas 400 mg/day added few further benefits. No peripheral vascular, AV nodal or adverse inotropic or electrocardiographic effects were observed. A minority of patients reported tremor and/or minor GI disturbances. In this large group of patients with chronic angina, bepridil was found to be an effective and well tolerated antianginal agent when given once daily.

UR - http://www.scopus.com/inward/record.url?scp=0020571288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020571288&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:0020571288

VL - 24

SP - 1307

EP - 1311

BT - Revue de Medecine

ER -